Stocks
Kindred Biosciences IncKIN
HealthcareBiotechnology
A biopharmaceutical company focused on developing and commercializing therapies for companion animals, particularly dogs and cats. Its pipeline includes treatments for conditions such as atopic dermatitis, congestive heart failure, and pain, with a strategy of repurposing approved human drugs for veterinary use. Investors track the company for its potential in the growing pet health market and its acquisition by Elanco Animal Health in 2022.
Congressional Interest in Kindred Biosciences Inc (KIN)
1 member of Congress has disclosed 1 trade in Kindred Biosciences Inc (KIN), a Healthcare company. The buy/sell breakdown shows 1 purchase versus 0 sales, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
1
Unique Politicians
1
Buys
1
Sells
0
Who in Congress Is Trading KIN?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2016-11-14 | MICHAEL T. MCCAUL | buy | $1K-$15K |